Ritrattodellasalute· @ritrattosalute · X·· 14 小时前评分70
正文 · 机器翻译
在 #ESMO26 上公布了 III 期研究 INTerpath-001 的数据，结果证实了一种 mRNA 治疗性疫苗对接受根治性手术的高危 #melanoma 患者有效：https://www.medinews.it/comunicati/melanoma-nuova-combinazione-riduce-del-42-il-rischio-di-recidiva-per-la-prima-volta-il-vaccino-terapeutico-e-efficace-contro-il-cancro/
@myESMO
49 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Ritrattodellasalute · x.com